Given the importance of finding markers that would help select candidates for treatment with bevacizumab, Bruhn et al. conducted a trial, in which they determined tumor expression levels of the proangiogenic proteins (IL-6, IL-8, b-FGF, PDGF-BB, and VEGF-A) in mCRC patients. The gene discussed is VEGFA; the disease is neoplasm.